New Full-Body scan could replace biopsies for breast cancer immunotherapy

NCT ID NCT05742269

Terminated Diagnosis Sponsor: Karolinska University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a special PET/CT scan that uses a radioactive tracer to see PD-L1 (a protein targeted by immunotherapy) throughout the body. The goal was to see if this scan could better identify which patients with metastatic triple-negative breast cancer would benefit from immunotherapy, compared to the standard biopsy method. Only 3 patients were enrolled before the study was terminated, so the findings are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 89Zr-atezolizumab (a radioactive tracer for PET/CT scans)
What this could lead to: If successful, this imaging method could help doctors choose the right immunotherapy for breast cancer patients without needing repeated biopsies.
What could go wrong: This was a very small, early study (only 3 participants planned) and was terminated early, so results are limited. The scan may not reliably predict who benefits from treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA

Contacts and locations

Locations

Karolinska University Hospital

Stockholm, 171 76, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.